

**HYPROCHON™**

Hydrolyzed Collagen with 10% Polysulfated Glycosaminoglycan (PSGAG)  
*Topical Wound Gel*

For Veterinary and Animal OTC Use

A combination device for wound care applications containing hydrolyzed collagen and polysulfated glycosaminoglycan (PSGAG). The hyCURE® hydrolyzed collagen when combined with chondroprotective agents such as Hymed's PSGAG become highly synergistic. This synergism allows each product's attributes to become more powerful and interactive. Hydrolyzed collagen with 10% PSGAG gel is made from natural materials that contain the proteins and amino acids that constitute the major building blocks of normal skin and connective tissue. The collagen forms a biological platform for new cell growth<sup>1</sup>; supplies nutritive protein directly to the cell/wound site(s)<sup>2</sup>; promotes and accelerates cellular regeneration<sup>3</sup>; and provides mechanical protection against physical and bacterial insult<sup>4</sup>. Hydrolyzed collagen has been experimentally tested as a hemostatic agent and as a tissue adhesive<sup>5</sup>. PSGAGs support and enhance the connective tissue and soft tissue while rehydrating dry wounds, protect from tissue trauma and maintain a moist healing environment.<sup>6,7,8</sup>

Hymed's PSGAG has been shown to prepare the granulation tissue for migration by maintaining a uniform, low density granulation tissue more easily modified by the migrating epithelium improving the rate of epithelialization (healing) of a full thickness wound and reducing scarring.<sup>9</sup>

**Description:** HYPROCHON™ is a gel composed of hydrolyzed collagen and 10% PSGAG; a preservative may or may not be added at client's request and post-sterilization can be added for "sterile" product status.

**Veterinary/Animal Indications:**

- ❖ Minor Abrasions
- ❖ Lacerations
- ❖ Minor Cuts
- ❖ Minor Scalds and Burns
- ❖ Surgical Wounds
- ❖ Skin Ulcers and Pressure Sores
- ❖ Other General Dermatological Conditions

**Characteristics and Attributes:**

- ❖ Provides a physiologically favorable environment that encourages wound healing
- ❖ Protects the wound bed and newly formed granulation tissue by the formation of an occlusive gelatinous barrier
- ❖ Reduces pain
- ❖ Conforms to any wound site
- ❖ Biocompatible and biodegradable
- ❖ Controls the evaporation of fluid
- ❖ Soothes and deodorizes
- ❖ Naturally highly absorbent
- ❖ Easy to handle and deliver
- ❖ Promotes natural autolysis by rehydrating and softening necrotic tissue and eschar thereby encouraging autolytic debridement

**Precautions and Contraindications:**

No known side effects. Contraindications for individuals with a known sensitivity to bovine or collagen.

**Product Administration:**

1. The wound site should be debrided and cleansed with sterile water or normal saline solution.
2. The skin surrounding the wound site should be dried, leaving the wound site moist.
3. Open the package and apply HYPROCHON™ directly onto the wound site (approximately ¼" thickness).
4. Apply a non-adherent dressing such as polyurethane film or gauze to the wound site.
5. Change dressing as needed. With subsequent dressing changes, any remaining HYPROCHON™ does not need to be removed.

**Storage:**

- ❖ Store at controlled room temperature (15 ° – 30 ° C)
- ❖ Protect from freezing

**How Supplied:**

HYPROCHON™ is supplied as a gel in 6 g, 28 g and 42 g tubes.

**References:** 1. Jain MK, Berg, RA. Material properties of hard tissue substitutes, Man.In Prep. 2. Stotts N, Tevis D. "Co-factors in impaired wound healing." Ostomy/Wound Management, 42:48, 1996. 3. Silver FH. Biological Materials, Structure, properties, and Modeling of Soft Tissues, NYU press 1987. 4. Chvapil M, Van Winkle Jr W. "Medical and surgical applications of collagen." International Review of Connective Tissue Research 6:36, 1973. 5. Cooper CW, Falb RD. Ann. N.Y. Acad.Sci. 146:214. 6. Lassus, A. Jeskahan, L., et al: Imdeen for the treatment of degenerated skin in females. Journal of Int'l Research. 19(2): 147-52. 7. Cooper, ML, Hansbrough, JF. Use of a composite skin graft composed of fibroblasts and a collagen-GAG matrix to cover full-thickness wounds. Surgery. Feb. 1991; 109(2): 198-207. 8. Breborowitz, A. , et al: Glycosaminoglycan chondroitin sulfate prevent loss of ultra filtration during peritoneal dialysis in rats. Nephron. 1994; 67(3): 346-50. 9. Data on file and available upon request from the company.

- ❖ The Hymed Group Corporation, 1817 Apple Tree Lane, Bethlehem, PA 18015; 01/24

The information given herein is believed to be reliable. However, no guarantee is made or liability assumed. The Hymed Group Corporation does not know all of the uses for which its products may be utilized or the condition of use. Therefore, The Hymed Group Corporation makes no claims or warranty concerning the fitness or suitability of the product for a particular use or purpose other than those outlined.